Abstract
Background Despite the importance of the transition to fatherhood as a critical life stage among young adult men, much remains unknown about the factors predictive of ideal cardiovascular health (CVH) and how CVH is impacted as young men face new roles and responsibilities associated with fatherhood.
Methods To address this gap, the Dad Bod Study is a prospective, longitudinal and observational study designed to examine how fatherhood affects young men’s CVH. A total of 125, first-time prospective fathers (men, 19-39 years) will be enrolled and followed over 1.5 years. Metrics of the American Heart Association’s “Life’s Essential 8” as well as demographic, social, and psychosocial factors will be collected at four time points ((baseline (during the pregnant partner’s 2nd trimester) 1-month postpartum, 6-months postpartum, and 1-year postpartum). The primary aims are to measure predictors of CVH among first-time fathers and describe longitudinal changes in CVH. A secondary aim is to identify best practices for recruitment, retention, and remote data collection in this population.
Summary The Dad Bod Study offers a novel examination of CVH among first-time fathers, exploring how new paternal roles and responsibilities impact cardiovascular health. Findings may provide key insights into critical CVH behaviors and risk factors to monitor, preserve, and improve as young men transition to fatherhood.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
This work was supported by the American Heart Association Career Development Award (https://doi.org/10.58275/AHA.24CDA1258755.pc.gr.193626). The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grants UL1 TR001414 and 1UM1TR004927. Partial funding for publishing this article open access was provided by the University of California Libraries under a transformative open access agreement with the publisher.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of California, Irvine Institutional Review Board (IRB #4907, approved May 1, 2024).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data sharing is not applicable to this protocol manuscript as no datasets were generated or analyzed. After study completion, the anonymized data and material will be made publicly available.
Non-Standard Abbreviation and Acronyms
- CE Studio
- Community Engagement Studio
- CVD
- Cardiovascular Disease
- CVH
- Cardiovascular Health
- SHAP
- Shapley Additive exPlanations
